MX2025010250A - Metodo para detectar una proteina de membrana celular - Google Patents
Metodo para detectar una proteina de membrana celularInfo
- Publication number
- MX2025010250A MX2025010250A MX2025010250A MX2025010250A MX2025010250A MX 2025010250 A MX2025010250 A MX 2025010250A MX 2025010250 A MX2025010250 A MX 2025010250A MX 2025010250 A MX2025010250 A MX 2025010250A MX 2025010250 A MX2025010250 A MX 2025010250A
- Authority
- MX
- Mexico
- Prior art keywords
- cell membrane
- membrane protein
- detecting cell
- embedded
- fixed tissue
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023050776 | 2023-03-28 | ||
| PCT/JP2024/012221 WO2024204325A1 (ja) | 2023-03-28 | 2024-03-27 | 細胞膜タンパク質を検出する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025010250A true MX2025010250A (es) | 2025-10-01 |
Family
ID=92906670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010250A MX2025010250A (es) | 2023-03-28 | 2025-08-29 | Metodo para detectar una proteina de membrana celular |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4692791A1 (https=) |
| JP (1) | JPWO2024204325A1 (https=) |
| KR (1) | KR20250166224A (https=) |
| CN (1) | CN120677381A (https=) |
| AU (1) | AU2024242849A1 (https=) |
| MX (1) | MX2025010250A (https=) |
| WO (1) | WO2024204325A1 (https=) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004003798T2 (de) | 2003-02-27 | 2007-10-11 | Dako Denmark A/S | Standard für immunhistochemie, immunzytologie und molekulare zytogenetika |
| JP2008527330A (ja) * | 2004-12-30 | 2008-07-24 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 低温の脱パラフィン処理 |
| EP2054083B1 (en) * | 2006-08-23 | 2013-11-27 | Korea Research Institute of Bioscience and Biotechnology | A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma |
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| KR101638490B1 (ko) | 2008-08-05 | 2016-07-11 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| US8067241B2 (en) | 2009-08-26 | 2011-11-29 | General Electric Company | Method and apparatus for antigen retrieval process |
| RU2598258C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112012018943A8 (pt) | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| JP6070191B2 (ja) | 2011-08-04 | 2017-02-01 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| KR102041832B1 (ko) | 2011-08-04 | 2019-11-08 | 도레이 카부시키가이샤 | 췌장암의 치료 및/또는 예방용 의약 조성물 |
| PT2740794T (pt) | 2011-08-04 | 2018-06-14 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| PT2832366T (pt) | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| KR102155531B1 (ko) | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
| PL2876447T3 (pl) * | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| KR20240005247A (ko) | 2016-10-28 | 2024-01-11 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JP7342701B2 (ja) | 2018-03-30 | 2023-09-12 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN113226329A (zh) * | 2018-12-28 | 2021-08-06 | 国立大学法人东京大学 | 识别癌细胞的抗体与链霉亲和素突变体的融合蛋白 |
| JP2023050776A (ja) | 2021-09-30 | 2023-04-11 | パナソニックＩｐマネジメント株式会社 | パネル装置 |
-
2024
- 2024-03-27 JP JP2024526940A patent/JPWO2024204325A1/ja active Pending
- 2024-03-27 WO PCT/JP2024/012221 patent/WO2024204325A1/ja not_active Ceased
- 2024-03-27 AU AU2024242849A patent/AU2024242849A1/en active Pending
- 2024-03-27 EP EP24780431.3A patent/EP4692791A1/en active Pending
- 2024-03-27 CN CN202480012001.XA patent/CN120677381A/zh active Pending
- 2024-03-27 KR KR1020257034502A patent/KR20250166224A/ko active Pending
-
2025
- 2025-08-29 MX MX2025010250A patent/MX2025010250A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120677381A (zh) | 2025-09-19 |
| AU2024242849A1 (en) | 2025-09-25 |
| EP4692791A1 (en) | 2026-02-11 |
| KR20250166224A (ko) | 2025-11-27 |
| WO2024204325A1 (ja) | 2024-10-03 |
| JPWO2024204325A1 (https=) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | Expression of catalytically active matrix metalloproteinase‐1 in dermal fibroblasts induces collagen fragmentation and functional alterations that resemble aged human skin | |
| Jadhav et al. | Metformin limits ceramide-induced senescence in C2C12 myoblasts | |
| RU2015153894A (ru) | Офтальмологическая линза с микрожидкостной аналитической системой | |
| DE602004028280D1 (de) | Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b-zellen | |
| MX2022002197A (es) | Metodo y aparato para el almacenamiento de informacion de movimiento. | |
| EP4303317A3 (en) | Removing and reinserting protein nanopores in a membrane using osmotic imbalance | |
| WO2019246160A3 (en) | Methods for assessing endometrial transformation | |
| MX2025010250A (es) | Metodo para detectar una proteina de membrana celular | |
| EA202190143A1 (ru) | Способ определения остаточного эксплуатационного ресурса мембраны для процесса разделения | |
| Higa et al. | Secretome of HepG2 cells infected with dengue virus: implications for pathogenesis | |
| Kawecki et al. | Inter-donor variability of extracellular matrix production in long-term cultures of human fibroblasts | |
| Stefanidis et al. | Telomere length in peripheral blood mononuclear cells of patients on chronic hemodialysis is related with telomerase activity and treatment duration | |
| Koizumi et al. | Increased permeability of the epithelium of middle ear cholesteatoma | |
| WO2005109555A3 (en) | System for and method of performing electrochemical tests of solid oxide fuel cells | |
| ES2182698B1 (es) | Procedimiento para la extraccion cuantitativa de gluten en alimentos procesados o no procesados por calor, y composicion solubilizante de proteinas de gluten o un kit comercial que la contenga necesarios para su puesta en practica. | |
| CL2021002854A1 (es) | Método para la predicción de eficacia del tratamiento de hemoglobinopatía | |
| Ofenbauer et al. | Dewaxed ECM: A simple method for analyzing cell behaviour on decellularized extracellular matrices | |
| Pottiez et al. | A differential proteomic approach identifies structural and functional components that contribute to the differentiation of brain capillary endothelial cells | |
| RU2008148606A (ru) | Способ экстракции компонентов из культуры дрожжевых клеток | |
| CO2021014146A2 (es) | Métodos para la cuantitación del inhibidor de la esterasa c1 funcional (inh-c1f) | |
| Korzeniewski et al. | Daughter centriole elongation is controlled by proteolysis | |
| Feng et al. | RAC1 regulate tumor necrosis factor‐α‐mediated impaired osteogenic differentiation of dental pulp stem cells | |
| PE20120793A1 (es) | Bioensayo de control de calidad para productos nutriceuticos y medicinales | |
| MX2022001800A (es) | Microelectrodo de ion selectivo de magnesio en estado solido mejorado y metodos de produccion y uso del mismo. | |
| BR112021023238A2 (pt) | Sistema para determinar o efeito dos ingredientes ativos em acariformes, insetos e outros organismos em uma placa de ensaio contendo furos |